Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — Investor Presentation (September 2020)
31 slides from Innate Pharma Sa Class A's investor presentation, September 2020
Slide 1: Company Overview September 2020
COMPANY OVERVIEW SEPTEMBER 2020 NASDAQ: IPHA EURONEXT PARIS: IPH
Slide 2: Forward Looking Statements
Forward Looking Statements This document has been prepared by Innate Pharma S.A. (the “Company”) solely for This presentation discusses product candidates that are under clinical development the purposes of a presentation to investors concerning the Company. This document and which have not yet been
Slide 3: Investment Highlights
Investment Highlights Monalizumab: advancing to Phase III in R/M SCCHN patients in 2020 triggering $50 million milestone upon dosing of the first patient and $50 million after a pre-planned interim analysis Broad and Diversified Lacutamab: in Phase II for mycosis fungoides; potential to validate
Slide 4: Our Strategy
Our Strategy We strive to achieve scientific leadership in immunotherapy by leveraging our expertise in innate immunity and transition to a commercial stage biotech Science Commercial Finance • Deliver the current • Build commercial • Continue to pipeline & prepare capabilities for strengthen financ
Slide 5: Innovative Approach to Immuno-Oncology
Innovative Approach to Immuno-Oncology Three-prong approach to harness the potential of the innate immune system Immune Checkpoint Tumor Antigen Tumor Micro Inhibitor Targeting Environment Unleash Target Relieve Endogenous Immune Killing Tumor cells Immune Suppression 5
Slide 6: Three Key Strategic Pillars to Harness the Potential of the Immune System
Three Key Strategic Pillars to Harness the Potential of the Immune System Phase of Development Program Target Indication PC Ph. I Ph. II Ph. III Commercial Partner Upcoming Milestone(s) 2H 2020: Expected Phase III initiation SCCHN Phase Ib/II 2021: Preliminary data from cohort 3 Immune Checkpoin
Slide 7: Monalizumab: First-in-Class Anti-NKG2A mAb
MONALIZUMAB FIRST-IN-CLASS ANTI-NKG2A MAB
Slide 8: First-in-Class Anti-NKG2A mAb
Monalizumab First-in-Class Anti-NKG2A mAb Promotes anti-tumor immunity by unleashing both T & NK cells Source: André, Vivier et al., Cell 2018 8
Slide 9: Lead Partnered Asset Advancing to Phase 3
Monalizumab Lead Partnered Asset Advancing to Phase 3 First program to advance into a Phase 3 study for patients with IO pre-treated SCCHN • 2H20: Phase 3 expected to start Phase 2 Expansion Cohort 2 o Monalizumab + cetuximab in IO-pretreated R/M Monalizumab + cetuximab, IO Pretreated R/M SCCHN** SC
Slide 10: Cohort 2: Preliminary Efficacy Results, Presented at ASCO20
Monalizumab Cohort 2: Preliminary Efficacy Results, Presented at ASCO20 Expansion cohort 2 confirmed prospectively the ORR reported in cohort 1 in IO-pretreated patients Expansion Cohort 2 ASCO20 Virtual Scientific Program: Monalizumab + cetuximab • “Combination of Monalizumab and IO Pretreated R/M
Slide 11: Key Results of Cetuximab Combination: Data from Cohort 1, ESMO 2019
Monalizumab Key Results of Cetuximab Combination: Data from Cohort 1, ESMO 2019 Acceptable safety profile, ORR of 27.5% and favorable trends in OS in post IO R/M SCCHN patients Mona + Cetuximab – Best Overall Response & ORR OS in All Patients All Patients IO-naïve IO-pretreated (n=40) (n=22) (n=18)
Slide 12: Cetuximab Combination – Key Preliminary Results
Monalizumab Cetuximab Combination – Key Preliminary Results Antitumor Activity: Best Change of Tumor Size from Baseline Source: Cohen et al., ESMO 2019 12
Slide 13: Monalizumab + Durvalumab Overview and Next Steps in MSS-CRC
Monalizumab Monalizumab + Durvalumab Overview and Next Steps in MSS-CRC Clinical activity shown in terms of duration and disease control rate in MSS-CRC supports further development • Presented data at ESMO 2019 from dose-exploration cohort in first-line therapy for MSS-CRC > Favorable safety and to
Slide 14: Lacutamab: First-in-Class Antibody Targeting KIR3DL2
LACUTAMAB FIRST-IN-CLASS ANTIBODY TARGETING KIR3DL2
Slide 15: First-in-Class Anti-KIR3DL2 mAb
Lacutamab First-in-Class Anti-KIR3DL2 mAb Lead proprietary asset • Lacutamab under development for the treatment of various forms of T-cell lymphomas (TCL) • FDA Fast Track designation for Sézary syndrome (SS) patients who have received at least two prior systemic therapies • Orphan drug designation
Slide 16: Phase I Clinical Efficacy Results
Lacutamab Phase I Clinical Efficacy Results Subgroup analysis All Sézary Prior treatment Sézary Syndrome Subgroup (n=35) SS without LCT 1 with syndrome (SS) N=28 mogamulizumab N=35 Best Global N=7 Response Best 42.9% 53.6% 42.9% Best change in mSWAT as compared to global (28.0 – 59.1) (35.8 – 70.5)
Slide 17: Lead Late-Stage Proprietary Asset, Helping to Build Rare Hem-Onc Franchise
Lacutamab Lead Late-Stage Proprietary Asset, Helping to Build Rare Hem-Onc Franchise A First-in-Class Anti-KIR3DL2 mAb TELLOMAK Phase II Study Cohort #1: Sézary Syndrome (N~60) ≥ 2 prior systemic therapies that must include mogamulizumab • Preliminary data in 2022 • 2H20: Resumed enrollment in • Pot
Slide 18: Avdoralimab, IPH5201, IPH5301
AVDORALIMAB (IPH5401) ANTI-C5AR ANTIBODY IPH5201 ANTI-CD39 ANTIBODY IPH5301 ANTI-CD73 ANTIBODY
Slide 19: Exploring Inflammation in COVID-19 and beyond
Avdoralimab Exploring Inflammation in COVID-19 and beyond COVID-19 severe pneumonia Other inflammatory diseases • FORCE Phase 2; enrollment ongoing • Targeting C5a/C5aR has been demonstrated • Published translational data in Nature supporting a scientifically and through positive clinical trials in
Slide 20: IPH5201 (Anti-CD39) and IPH5301 (Anti-CD73)
IPH5201 – IPH5301 IPH5201* (Anti-CD39) and IPH5301 (Anti-CD73) Targeting immunosuppressive tumor microenvironment • CD39 and CD73 are enzymes expressed on different cells in the TME Promote immuno-suppression by degrading pro-inflammatory ATP into immunosuppressive adenosine • Ongoing Phase 1 tria
Slide 21: IPH5201 – Preclinical Data
IPH5201 IPH5201* – Preclinical Data Significant tumor responses observed in response to treatment with PD-1 inhibitors and ADCC- inducing antibodies, as well as with immunogenic chemotherapy, compared to responses to these agents in wild-type mice Sources: Perrot Cell Reports 2019 *2018 potential li
Slide 22: IPH5301 – Preclinical Data
IPH5301 IPH5301 – Preclinical Data IPH5301 more potent in restoring CD4+ and CD8+ T-cell proliferation in an ATP- suppression assay, than the most advanced clinical candidates + + C D 4 T c e lls C D 8 T c e lls ( n o r m a liz e d t o c o n tr o l) * * * 1 0 0 P r o life r a tio n r a te 1 0 0 * *
Slide 23: Commercial: Lumoxiti
eres pharma COMMERCIAL LUMOXITI
Slide 24: Lumoxiti: First-in-class Marketed Product In-Licensed from AZ for HCL
Lumoxiti A First-in-class, Marketed Product In-Licensed from AZ for the Treatment of HCL First FDA-approved treatment for hairy cell leukemia in over 20 years Largest trial to date (N=80) in patients with R/R HCL who First-in-class CD22-directed immunotoxin failed at least 2 prior therapies Approv
Slide 25: Establishing Commercial Footprint in Rare-Hem-Oncology
Lumoxiti Establishing Commercial Footprint in Rare-Hem-Oncology Full Transition from AstraZeneca on-track by end of year Establish US Commercial Fully Independent, Drive Lumoxiti Sales Organization Building Franchise • Establish Innate as a • Recruited experienced US team • By end of the year, US co
Slide 26: Market Opportunity for Lumoxiti
Lumoxiti Market Opportunity for Lumoxiti 2020 sales impacted by COVID-19 Critical Success Market Opportunity COVID-19 Factors • 3L HCL patients; 380 patients in • Reaching beyond centers of • Impacted face-to-face US excellence (COEs) / academic interactions across the centers as patients are manage
Slide 27: Summary
Summary Progress across our portfolio • Lacutamab TELLOMAK study resumed 1 • Monalizumab moving to Phase 3 • Exploring avdoralimab in inflammation Established US commercial infrastructure for Lumoxiti 2 • Creating foundation for future rare hem-oncology franchise Momentum to continue in 2H20 & 2021
Slide 28: Anticipated Major Newsflow
Anticipated Major Newsflow Lumoxiti Lumoxiti Complete commercial Potential EU approval transition Monalizumab Monalizumab Preliminary data Ph 3 initiation + $50m milestone Expansion Cohort 3 SCCHN Monalizumab Updated data expansion Cohort 2 SCCHN Avdoralimab Lacutamab Lacutamab Initiate investigator
Slide 29: Appendix
eres pharma APPENDIX
Slide 30: AstraZeneca Deals – Key Highlights
AstraZeneca Deals – Key Highlights Monalizumab IPH5201 Additional 4 Preclinical Molecules • Payment at signing and Opt-in Payment (2015, • Upfront Payments: • Upfront Payments: 2018) > USD50m > USD20m (for all targets) > USD 350m • Near Term and Opt-in Future Payments: • Opt-in Future Payments: • Ne
Slide 31: First Half 2020 Financial Highlights
First Half 2020 Financial Highlights In thousands of euros, except for data per share June 30, 2020 December 31, 2019 Revenue and other income 36,745 59,155 Research and development (31,499) (36,584) Selling, general and administrative (14,490) (9 295) Total operating expenses (45,989) (45,879) Net
Innate Pharma — Investor Presentation (September 2020) on 6ix